Asthma Related Death
- Long acting beta2-adrenergic agonists (LABA) increase the risk of asthma related death.
- Data from a large placebo-controlled US study that compared the safety of another long acting beta2-adrenergic agonist (salemterol) or placebo added to usual asthma therapy showed an increase in asthma related deaths in patients receiving salmeterol.
- This finding with salmeterol is considered a class effect of LABA, including indacaterol, the active ingredient in Arcapta Neohaler.
- The safety and efficacy of Arcapta Neohaler in patients with asthma have not been established.
- Indacaterol is not indicated for the treatment of asthma. [See contraindications, Warninigs and Precautions]
Patient Counseling Information
Updated January 2018